SLC5A2 and cardiomyopathy: There is also a need to test potential mitigating therapies such as SGLT2 inhibitors, small molecule activators of mitochondrial fusion, and mitochondrial antioxidants like Coenzyme Q10 or mitoquinone which ameliorate mitochondria-mediated cardiomyopathy in other conditions [27,28,29,30,31,32].